 |
Technologiepark Website: www.affimed.com |
| Branche: | Biotechnology |
| Produkte/Dienstleistungen: | Bispecific antibodies to activate the innate immune system of patients with cancer (currently in pre-clinical and clinical development) |
| Standort(e): | Heidelberg, Germany New York City, USA |
| Gründungsdatum: | 2000 |
| Mitarbeiterzahl: | 140 |
| Das Unternehmen | Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. |
| Angebotene Stellen pro Jahr: | 40 |
| Gesuchte Fachrichtungen: |
Biowissenschaften Biochemie Biotechnologie Chemie Program Management Quality Assurance Regulatory Affairs Clinical Operations Statistics |
| Gesuchte Abschlüsse: |
PostDoc PhD Master Bachelor Technische Assistenten |
| Zusatzqualifikationen (soft skills): | Good English language skills are favorable |
| Einstiegsmöglichkeiten: | Direct entry |
| Traineeprogramme (Zahl der Plätze /Jahr): | Nein |
| Kontakt: | Affimed GmbH Susanne Hering Im Neuenheimer Feld 582 69120 Heidelberg s.hering [at] affimed.com |